Clinical Trial Search

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001

Primary: Proportion Of Participants In The Microbiological Modified Intent-To-Treat (m-MITT) Population Who Achieved Overall Success At The End Of Intravenous Treatment Visit…

Primary: Postoperative Pain — 3; 4.5; 8; 8 units on a scale

Primary: The Primary Objective of the Study is to Compare Between the Two Groups, the Number of Subjects Alive and Extubated at 48 Hours Post Surfactant Administration…

Primary: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm — 94; 94 Percentage of participants

Primary: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) — -1.25; -1.22 Percentage of glycosylated hemoglobin — p=0.693

Primary: Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24 — 0.08; -1.01 Ratio — p=< 0.0001

Primary: Relapse — 66; 99 Participants

Primary: Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score — -3.2 units on a scale

Primary: Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 48 — 1.34; 0.05 Percent change — p=0.014

Primary: Mean Change in BCVA by ETDRS Letter Score From Baseline — 10.5; 7.3; 9.2; 10.5 ETDRS BCVA Letters

Primary: Assessment of Erectile Dysfunction — 64; 64; 59.00; 58 units on a scale

Primary: Pain Levels on a Visual Analog Scale ( VAS) — 7.05; 4.03; 7.49; 6.60 units on a scale — p=<0.10

Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 1-hour (SPID1). — 2.11 units on a scale

Primary: Number of Subjects With Vaccine Response to Meningococcal Serogroup C Serum Based on a Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody — 254; 88…